Wealth Enhancement Advisory Services
JAZZ icon

Wealth Enhancement Advisory Services’s Jazz Pharmaceuticals JAZZ Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.1M Buy
18,651
+8,212
+79% +$1.8M 0.01% 1140
2026
Q1 		$1.95M Buy
10,439
+1,082
+12% +$189K ﹤0.01% 1402
2025
Q4 		$1.56M Buy
9,357
+3,182
+52% +$488K ﹤0.01% 1673
2025
Q3 		$848K Buy
6,175
+746
+14% +$89.5K ﹤0.01% 1972
2025
Q2 		$594K Buy
5,429
+1,095
+25% +$119K ﹤0.01% 2098
2025
Q1 		$538K Buy
4,334
+232
+6% +$30.3K ﹤0.01% 2009
2024
Q4 		$505K Buy
4,102
+743
+22% +$87.6K ﹤0.01% 1988
2024
Q3 		$374K Sell
3,359
-192
-5% -$21K ﹤0.01% 2031
2024
Q2 		$379K Buy
3,551
+768
+28% +$84.4K ﹤0.01% 1820
2024
Q1 		$335K Buy
2,783
+202
+8% +$24.7K ﹤0.01% 1844
2023
Q4 		$317K Sell
2,581
-410
-14% -$51.2K ﹤0.01% 1776
2023
Q3 		$387K Buy
+2,991
New +$399K ﹤0.01% 1586

Other funds holding JAZZ

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
ACM
Argent Capital Management St Louis, Missouri $3.17B AUM 36.16% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
PL
Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
BCM
BTC Capital Management Des Moines, Iowa $1.65B AUM 27.85% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Wealth Enhancement Advisory Services's JAZZ Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its Jazz Pharmaceuticals (JAZZ) stake by 79% in Q2 2026, buying an estimated $1.8M and bringing the position to 18,651 shares worth $4.1M. The position accounts for 0.01% of the portfolio, ranked #1140.

Wealth Enhancement Advisory Services first reported a position in JAZZ in Q3 2023 and has held it in 12 quarters since. 84 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Wealth Enhancement Advisory Services held 18,651 shares of Jazz Pharmaceuticals worth $4.1M as of Q2 2026.
  • Wealth Enhancement Advisory Services bought 8,212 Jazz Pharmaceuticals shares in Q2 2026, an estimated $1.8M.
  • Jazz Pharmaceuticals made up 0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #1140 holding.
  • Wealth Enhancement Advisory Services first reported a position in Jazz Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • 84 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.